| Identification | Back Directory | [Name]
DEXLOXIGLUMIDE | [CAS]
119817-90-2 | [Synonyms]
DEXLOXIGLUMIDE
-5-((3-methoxypropyl)
-4-(3,4-Dichlorobenzamido)
(R)-4-(3,4-DichlorobenzaMido)-5-((3-Methoxypropyl)(pentyl)aMino)-5-oxopentanoic acid
(R)-4-(3,4-Dichlorobenzoylamino)-5-[(3-methoxypropyl)pentylamino]-5-oxopentanoic acid
pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (4r)-
(4R)-4-[[(3,4-dichlorophenyl)-oxomethyl]amino]-5-[3-methoxypropyl(pentyl)amino]-5-oxopentanoic acid | [Molecular Formula]
C21H30Cl2N2O5 | [MDL Number]
MFCD00866773 | [MOL File]
119817-90-2.mol | [Molecular Weight]
461.38 |
| Chemical Properties | Back Directory | [Boiling point ]
632.2±55.0 °C(Predicted) | [density ]
1.233±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
DMSO: 50 mg/ml, sonicated | [form ]
A solid | [pka]
4.48(at 25℃) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist[1]. Dexloxiglumide, the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8)[2]. | [Definition]
ChEBI: Dexloxiglumide is a glutamic acid derivative. | [References]
[1] Scarpignato C, et al. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9. DOI:10.1111/j.0953-0673.1996.00411.x
[2] Maselli MA, et al. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterol Dietol. 2003 Sep;49(3):211-6. PMID:16484960 |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|